18 F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

• Published in: Schizophrenia research 2010, Vol.122 (1), p.43-52
• Main Authors: Lehrer, Douglas S, Christian, Bradley T, Kirbas, Cemil, Chiang, Meicheng, Sidhu, Shawn, Short, Holly, Wang, Binquan, Shi, Bingzhi, Chu, King-Wai, Merrill, Brian, Buchsbaum, Monte S
• Format: Article
• Language: English
• Subjects: Psychiatry
• ISSN: 0920-9964
• DOI: 10.1016/j.schres.2010.03.043

Abstract Background Molecular imaging of dopaminergic parameters has contributed to the dopamine hypothesis of schizophrenia, expanding our understanding of pathophysiology, clinical phenomenology and treatment. Our aim in this study was to compare18 F-fallypride binding potential BPND in a group of patients with schizophrenia-spectrum illness vs. controls, with a particular focus on the cortex and thalamus. Methods We acquired18 F-fallypride positron emission tomography images on 33 patients with schizophrenia spectrum disorder (28 with schizophrenia; 5 with schizoaffective disorder) and 18 normal controls. Twenty-four patients were absolutely neuroleptic naïve and nine were previously medicated, although only four had a lifetime neuroleptic exposure of greater than two weeks. Parametric images of18 F-fallypride BPND were calculated to compare binding across subjects. Results Decreased BPND was observed in the medial dorsal nucleus of the thalamus, prefrontal cortex, lateral temporal lobe and primary auditory cortex. These findings were most marked in subjects who had never previously received medication. Conclusions The regions with decreased BPND tend to match brain regions previously reported to show alterations in metabolic activity and blood flow and areas associated with the symptoms of schizophrenia.